Shanghai Junshi Biosciences Co.,Ltd.(688180),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

688180 Shanghai Junshi Biosciences Co.,Ltd.

Closed 04-18 15:00:00

28.70

-0.15

-0.52%

High29.20	Low28.39	Vol3.69M
Open28.83	D1 Closing28.85	Amplitude2.81%
Mkt Cap28.30B	Tradable Cap21.96B	Total Shares986.00M
T/O106.00M	T/O Rate0.48%	Tradable Shares765.00M
P/B4.83	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"Shanghai Junshi Biosciences Co.,Ltd.","latestPrice":28.7,"timestamp":1744959600000,"preClose":28.85,"halted":0,"volume":3691403,"delay":0,"changeRate":-0.0052,"floatShares":765000000,"shares":986000000,"eps":-0.2825,"marketStatus":"Closed","change":-0.15,"latestTime":"04-18 15:00:00","open":28.83,"high":29.2,"low":28.39,"amount":106000000,"amplitude":0.0281,"askPrice":28.7,"askSize":5,"bidPrice":28.69,"bidSize":134,"shortable":0,"etf":0,"ttmEps":-0.2825,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745199000000},"marketStatusCode":5,"adr":0,"adjPreClose":28.85,"symbolType":"stock_kcb","openAndCloseTimeList":[[1744939800000,1744947000000],[1744952400000,1744959600000]],"highLimit":31.74,"lowLimit":25.97,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":985689871,"isCdr":false,"pbRate":4.83,"roa":"--","roe":"--","epsLYR":-1.3,"committee":0.875817,"marketValue":28289000000,"turnoverRate":0.0048,"status":1,"nextConnectDate":"Northbound have stopped. The next trading day is UTC+8 2025-04-22.","afterMarket":{"amount":0,"volume":0,"close":28.7,"buyVolume":0,"sellVolume":0,"time":1744961638142,"indexStatus":"Closed 04-18 15:30:00","preClose":28.85},"hkstockBrief":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"JUNSHI BIO","latestPrice":14.24,"timestamp":1744877289031,"preClose":14.32,"halted":0,"volume":1019400,"delay":0,"premium":"-53.33"},"floatMarketCap":21943000000},"requestUrl":"/m/hq/s/688180","defaultTab":"news","newsList":[{"id":"2526988576","title":"Junshi Biosciences  Says Chairman Plans to Boost Holdings in Co a/H-Shares Worth at Least 100 Mln Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2526988576","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526988576?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 22:02","pubTimestamp":1744380155,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nL3N3QP193:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688180","BK0239"],"gpt_icon":0},{"id":"2526769850","title":"BRIEF-Junshi Biosciences Says Chairman To Boost Holdings In Co A/H-Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2526769850","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526769850?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 22:02","pubTimestamp":1744380155,"startTime":"0","endTime":"0","summary":"BRIEF-Junshi Biosciences Says Chairman To Boost Holdings In Co A/H-SharesApril 11  - Shanghai Junshi Biosciences Co Ltd 688180.SS:SAYS CHAIRMAN PLANS TO BOOST HOLDINGS IN CO A/H-SHARES WORTH AT LEAST 100 MILLION YUAN Source textFurther company coverage: 688180.SS  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nL3N3QP193:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688180"],"gpt_icon":0},{"id":"2523656792","title":"Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2523656792","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523656792?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 09:35","pubTimestamp":1743212147,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250329:nTUA8TYPWL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","688180"],"gpt_icon":0},{"id":"2523656797","title":"Junshi Biosciences FY Revenue RMB 1,948 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2523656797","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523656797?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 09:35","pubTimestamp":1743212147,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250329:nPLXC2C6EF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688180","BK0239"],"gpt_icon":0},{"id":"2522514022","title":"Shanghai Junshi Biosciences 2024 Loss Shrinks 44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522514022","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522514022?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 15:32","pubTimestamp":1743147130,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences  reported that loss attributable to owners for 2024 narrowed by 44% to 1.28 billion yuan, from the 2.28 billion yuan loss a year earlier, according to a Thursday filing with the Hong Kong bourse.Loss per share was 1.30 yuan, from 2.32 yuan loss per share a year ago.Revenue rose 30% to 1.95 billion yuan from 1.50 billion yuan the previous year.The company's shares were up 6% at the Hong Kong bourse and 2% at the Shanghai bourse in recent trading.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK1583","BK0239","01877","BK1515","688180"],"gpt_icon":0},{"id":"2522869785","title":"BRIEF-Shanghai Junshi Biosciences Posts FY Loss Attributable Of RMB1,282 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2522869785","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522869785?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 23:50","pubTimestamp":1743090608,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Junshi Biosciences Posts FY Loss Attributable Of RMB1,282 MlnMarch 27  - Shanghai Junshi Biosciences Co Ltd 688180.SS:LOSS ATTRIBUTABLE FOR YEAR RMB1,282 MILLIONAS AT 31 DECEMBER 2024, TOTAL REVENUE RMB1,948 MILLIONFurther company coverage: 688180.SS ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nFWN3QA1BM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1161","01877","BK1515","688180","BK0239"],"gpt_icon":0},{"id":"2522301111","title":"Shanghai Junshi Biosciences - as at 31 December 2024, Total Revenue RMB1,948 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2522301111","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522301111?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 21:54","pubTimestamp":1743083681,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nFWN3QA1BM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688180","01877","BK0239","BK1515","BK1583","BK1161"],"gpt_icon":0},{"id":"2522322189","title":"BRIEF-Shanghai Junshi Biosciences's 2024 Net Loss At 1.3 Billion Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2522322189","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522322189?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 18:16","pubTimestamp":1743070618,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Junshi Biosciences's 2024 Net Loss At 1.3 Billion YuanMarch 27  - Shanghai Junshi Biosciences Co Ltd 688180.SS:SAYS 2024 NET LOSS 1.3 BILLION YUAN Source textFurther company coverage: 688180.SS  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nL3N3QA0TQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688180"],"gpt_icon":0},{"id":"2522228233","title":"Shanghai Junshi Biosciences  Says 2024 Net Loss 1.3 Bln Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2522228233","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522228233?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 18:16","pubTimestamp":1743070618,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nL3N3QA0TQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688180","BK0239"],"gpt_icon":0},{"id":"2522345231","title":"Chinese Shares Rise Despite Dip in Industrial Profit; Zhejiang China Commodities City Jumps 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522345231","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522345231?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 16:04","pubTimestamp":1743062650,"startTime":"0","endTime":"0","summary":"Chinese shares saw moderate gains on Thursday, even as data revealed a slight decline in industrial profits for the first two months of the year.The Shanghai Composite Index, the main gauge of Chinese","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","688180","BK0196","LU1064130708.USD","BK0137","BK1583","BK0032","BK0060","LU1064131003.USD","600276","BK0000","LU0405327494.USD","BK0201","600415","BK4211","CHCO","BK0188","BK0118","LU0405327148.USD","BK0183","BK0012","LU2148510915.USD","LU2488822045.USD","BK0210","LU1328615791.USD","LU1969619763.USD","LU2328871848.SGD","01877","BK0028","BK1515","BK1161","BK0107"],"gpt_icon":0},{"id":"2522080283","title":"BRIEF-Shanghai Junshi Biosciences Gets Approval By HSA For Marketing Of Toripalimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2522080283","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522080283?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 21:49","pubTimestamp":1742996983,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Junshi Biosciences Gets Approval By HSA For Marketing Of ToripalimabMarch 26 (Reuters) - Shanghai Junshi Biosciences Co Ltd 688180.SS:APPROVAL BY HSA FOR MARKETING OF TORIPALIMABFurther company coverage: 688180.SS ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90DP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1161","01877","688180","BK1583","BK0239"],"gpt_icon":0},{"id":"2522871155","title":"Shanghai Junshi Biosciences - Approval by Hsa for Marketing of Toripalimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2522871155","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522871155?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 19:55","pubTimestamp":1742990132,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90DP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1161","01877","688180","BK1583","BK0239"],"gpt_icon":0},{"id":"2521350756","title":"Junshi Biosciences Gets Nod to Market Hepatocellular Carcinoma Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2521350756","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521350756?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 11:56","pubTimestamp":1742788577,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences  received approval from China's National Medical Products Administration to market toripalimab injection, according to a Hong Kong Stock Exchange filing on May 21.The drug, trading under the name Tuoyi, is used in combination with bevacizumab for the treatment of unresectable or metastatic hepatocellular carcinoma, the pharmaceutical company said.Both of the company's Hong Kong and Shanghai shares slipped 1% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01877","BK0239","BK1515","688180","BK1583","BK1161"],"gpt_icon":0},{"id":"2521755068","title":"Junshi Biosciences Announces Approval of Snda for Toripalimab in Combination With Bevacizumab for 1St-Line Treatment of Advanced Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2521755068","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521755068?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 11:53","pubTimestamp":1742788428,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nTUA55SLSP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688180","BK0239"],"gpt_icon":0},{"id":"2521332422","title":"BRIEF-Shanghai Junshi Biosciences Announces Approval Of Supplemental New Drug Application For Toripalimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2521332422","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521332422?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 22:53","pubTimestamp":1742568832,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Junshi Biosciences Announces Approval Of Supplemental New Drug Application For ToripalimabMarch 21  - Shanghai Junshi Biosciences Co Ltd 688180.SS:APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION FOR TORIPALIMAB IN COMBINATION WITH BEVACIZUMAB BY NMPAFurther company coverage: 688180.SS ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nFWN3Q31AV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688180","01877","BK1583","BK1161","BK0239","BK1515"],"gpt_icon":0},{"id":"2521076374","title":"Shanghai Junshi Biosciences -  Approval of Supplemental New Drug Application for Toripalimab in Combination With Bevacizumab by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2521076374","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521076374?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 19:28","pubTimestamp":1742556488,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nFWN3Q31AV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01877","BK1161","688180","BK1583","BK1515","BK0239"],"gpt_icon":0},{"id":"2521939449","title":"Junshi Bio Gets China Nod to Trial Advanced Tumor Drug; Hong Kong Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2521939449","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521939449?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 11:33","pubTimestamp":1742527995,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences  will conduct clinical trials on JS212 injection after receiving approval from China's National Medical Products Administration, according to a Hong Kong Stock Exchange disclosure on Thursday.The drug will be tested as a treatment for advanced malignant solid tumors in conditions such as lung cancer, breast cancer, and head and neck cancer, the pharmaceutical company said.Junshi Bio's Hong Kong shares dropped over 4% and Shanghai shares fell less than 2% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01877","688180","IE00B7SZL793.SGD","BK0239","BLZ.SI","IE0031619046.USD","BK6088","BK1515","AEIS","BK1161","BK4157","BK1583","IE00B19Z4B17.USD","IE00B66KJ199.SGD","BK6522"],"gpt_icon":0},{"id":"2514342665","title":"Junshi Biosciences' 2024 Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2514342665","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514342665?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 18:56","pubTimestamp":1740740209,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences'  attributable loss narrowed to 1.28 billion yuan in 2024 from 2.28 billion yuan in 2023, according to a Thursday filing with the Hong Kong Exchange.Loss per share at the drug company fell to 1.30 yuan from 2.32 yuan in the previous year.Total operating income grew 30% to 1.94 billion yuan from 1.50 billion yuan a year earlier.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01877","688180","BK0239","BK1515","BK1161","BK1583"],"gpt_icon":0},{"id":"2514527822","title":"Junshi Biosciences  Prelim 2024 Net Loss at 1.3 Bln Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2514527822","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514527822?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 16:30","pubTimestamp":1740645046,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nL3N3PI0O3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","688180"],"gpt_icon":0},{"id":"2514504822","title":"BRIEF-Junshi Biosciences' Prelim 2024 Net Loss At 1.3 Billion Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2514504822","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514504822?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 16:30","pubTimestamp":1740645046,"startTime":"0","endTime":"0","summary":"BRIEF-Junshi Biosciences' Prelim 2024 Net Loss At 1.3 Billion YuanFeb 27  - Shanghai Junshi Biosciences Co Ltd 688180.SS:PRELIM 2024 NET LOSS AT 1.3 BILLION YUAN Source textFurther company coverage: 688180.SS  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nL3N3PI0O3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688180"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-07-15","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路987号4层","stockEarnings":[{"period":"1week","weight":-0.0171},{"period":"1month","weight":-0.0534},{"period":"3month","weight":0.109},{"period":"6month","weight":-0.0842},{"period":"1year","weight":0.1508},{"period":"ytd","weight":0.0501}],"companyName":"上海君实生物医药科技股份有限公司","boardCode":"AI0027","perCapita":"26048股","boardName":"医药制造业","registeredCapital":"98568万元","compareEarnings":[{"period":"1week","weight":0.0119},{"period":"1month","weight":-0.0437},{"period":"3month","weight":0.0108},{"period":"6month","weight":0.0047},{"period":"1year","weight":0.0659},{"period":"ytd","weight":-0.0224}],"survey":"　　上海君实生物医药科技股份有限公司的主营业务是新药的研发及相关技术的转让和服务，新药的生产和销售。公司的主要产品是特瑞普利单抗、氢溴酸氘瑞米德韦片、Tifcemalimab、阿达木单抗、昂戈瑞西单抗、重组人源化抗IL-17A单克隆抗体、重组人源化抗PD-1、VEGF双特异性抗体、靶向ANGPTL3mRNA的siRNA药物、重组人源化抗CGRP单克隆抗体、PI3K-α抑制剂、重组人源化抗Claudin18.2单抗-MMAE偶联剂。公司拥有175项已授权专利，其中129项为境内专利，46项为境外专利。公司专利覆盖新药蛋白结构、制备工艺、用途、制剂配方等，为公司产品提供充分的和长生命周期的专利保护。","serverTime":1745064460106,"listedPrice":55.5,"stockholders":"29351人(较上一季度增加0.89%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shanghai Junshi Biosciences Co.,Ltd.(688180),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shanghai Junshi Biosciences Co.,Ltd.(688180) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shanghai Junshi Biosciences Co.,Ltd.,688180,Shanghai Junshi Biosciences Co.,Ltd.股票,Shanghai Junshi Biosciences Co.,Ltd.股票老虎,Shanghai Junshi Biosciences Co.,Ltd.股票老虎国际,Shanghai Junshi Biosciences Co.,Ltd.行情,Shanghai Junshi Biosciences Co.,Ltd.股票行情,Shanghai Junshi Biosciences Co.,Ltd.股价,Shanghai Junshi Biosciences Co.,Ltd.股市,Shanghai Junshi Biosciences Co.,Ltd.股票价格,Shanghai Junshi Biosciences Co.,Ltd.股票交易,Shanghai Junshi Biosciences Co.,Ltd.股票购买,Shanghai Junshi Biosciences Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shanghai Junshi Biosciences Co.,Ltd.(688180),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shanghai Junshi Biosciences Co.,Ltd.(688180) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}